Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation

Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation

The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.

PCI with coronary stent implantation is performed for a huge number of patients with coronary artery disease. Approximately 20% of these patients undergo non-cardiac surgery within three years after PCI. However, there is a scarcity of clinical evidence regarding the efficacy of perioperative aspirin continuation on cardiovascular events.

Inclusion Criteria:

• Patients with a history of coronary stenting and scheduled for abdominal surgery
• Patients on a single antiplatelet agent

Exclusion Criteria:

• Patients on dual antiplatelet therapy (DAPT)
• Patients on anticoagulation therapy
• Patients with a history of stent thrombosis
• Patients with CHADS2 score >= 5
• Patients at extremely high risk of bleeding and unable to continue preoperative aspirin
• Patients incapable of consent, including those under 20 years of age
• Other patients for whom either discontinuation or continuation of antiplatelet agents is deemed inappropriate by the attending physician